IONC101
/ University of Florida, iOncologi
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
November 06, 2025
Design of messenger RNA vaccines based on lipid-polymer hybrid nanoparticles.
(PubMed, J Control Release)
- "Upon vaccination and SARS-CoV-2 challenge of Syrian golden hamsters, mRNA-LPNs induced high spike-specific IgG responses and were more efficient in reducing the SARS-CoV-2 load in the nasal cavity, compared to mRNA-LNPs. Hence, mRNA-LPN vaccines are viable alternatives to conventional mRNA-LNPs due to their restricted protein expression at the intramuscular injection site and enhanced ability to reduce the SARS-CoV-2 burden in the nasal cavity of infected hamsters."
Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD8
October 03, 2025
mRNA fusion-targeted vaccination elicits immune-mediated tumor killing
(SITC 2025)
- "The median IFN-γ release in the group treated with fusion-targeted vaccinated splenocytes was almost 3x that of the group treated with unvaccinated splenocytes (219 pg/ml vs. 622 pg/ml, p=0.11).Conclusions Splenocytes trained with the fusion-targeted mRNA-LPA vaccine in naïve mice effectively produced an adaptive immune response against fusion positive tumor spheroids. Further quantification of immune cell mobilization and identification of targeted antibodies will be performed. This data provides crucial evidence to support FDA application for an investigational new drug for clinical translation toward targeting tumor-driving fusion oncoproteins via mRNA-LPA vaccination."
Ewing Sarcoma • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • EWSR1 • FLI1 • IFNG
July 22, 2025
Antitumor response of tumor-specific mRNA-LPA vaccine in syngeneic mouse model of BRAFV600E-driven ATC.
(ATA 2025)
- "Remarkably, the combination of dabrafenib+trametinib yielded a 69% overall response rate in patients with BRAFV600E-driven ATCs and led to FDA approval. Discussion/Conclusion Our results suggest that the mRNA–LPA vaccine is a novel therapeutic approach that could improve outcomes for ATC patients. The novel, patented lipid particle used to create the vaccine is approved under two separate FDA INDs and is in phase I clinical trials for multiple solid tumors, making the translation of the total tumor mRNA–LPA vaccine to ATC patients highly feasible."
Preclinical • Oncology • Solid Tumor • Thyroid Gland Anaplastic Carcinoma • Thyroid Gland Carcinoma
April 23, 2025
Murine metastatic embryonal rhabdomyosarcoma survival and immune response with a total tumor RNA lipid particle aggregate vaccine.
(ASCO 2025)
- "An immunogenic murine model of RMS with pulmonary metastases experienced a survival benefit with our ttRNA-LPA vaccine. Non-specific RNA provided some benefit likely owing to the robust innate immune response and may support development of a non-personalized vaccine for STS. These data directly support translation to human clinical trial for STS."
Metastases • Preclinical • Brain Cancer • Glioblastoma • Lung Cancer • Melanoma • Oncology • Osteosarcoma • Pediatrics • Rhabdomyosarcoma • Sarcoma • Solid Tumor
May 01, 2024
Novel mRNA Vaccine Shows Promise Against Deadly Brain Cancer
(Neuroscience News)
- P=NA | N=4 | "In a first-ever human clinical trial of four adult patients, an mRNA cancer vaccine developed at the University of Florida quickly reprogrammed the immune system to attack glioblastoma, the most aggressive and lethal brain tumor...The results mirror those in 10 pet dog patients suffering from naturally occurring brain tumors whose owners approved of their participation, as they had no other treatment options, as well as results from preclinical mouse models...The breakthrough now will be tested in a Phase 1 pediatric clinical trial for brain cancer...While too early in the trial to assess the clinical effects of the vaccine, the patients either lived disease-free longer than expected or survived longer than expected...The next step, through support from the Food and Drug Administration and the CureSearch for Children’s Cancer foundation, will be an expanded Phase I clinical trial to include up to 24 adult and pediatric patients..."
Clinical data • Preclinical • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor
1 to 5
Of
5
Go to page
1